Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular Dystrophy

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|12|3|245-259

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.12, Iss.3, 2012-06, pp. : 245-259

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod   Rodino-Klapac Louise R.   Mendell Jerry R  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite

Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy

By ’t Hoen Peter AC   van der Wees Caroline GC   Aartsma-Rus Annemieke   Turk Rolf   Goyenvalle Aurélie   Danos Olivier   Garcia Luis   van Ommen Gert-Jan B   den Dunnen Johan T   van Deutekom Judith CT  

Pharmacogenomics, Vol. 7, Iss. 3, 2006-04 ,pp. : 281-297

Future Medicine

Access to resources Recommend Favorite

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

By Judge Daniel P.   Kass David A.   Thompson W. Reid   Wagner Kathryn R.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite

Duchenne muscular dystrophy drug discovery – the application of utrophin promoter activation screening

By Moorwood Catherine   Khurana Tejvir S  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 5, 2013-06 ,pp. : 569-581

Informa Healthcare

Access to resources Recommend Favorite

Deflazacort helps to maintain both muscle and pulmonary function in Duchenne muscular dystrophy

By  

Inpharma, Vol. 1, Iss. 1275, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite